Tscan Announces Collaboration With Novartis On The Discovery And Development Of Novel T Cell Receptor Therapies For The Treatment Of Solid Tumors

Tscan Announces Collaboration With Novartis On The Discovery And Development Of Novel T Cell Receptor Therapies For The Treatment Of Solid Tumors

By, Admin 17 April 2020

Tscan Therapeutics, A Biopharmaceutical Company Focused On The Development Of T Cell Receptor (Tcr) Therapies Which Reprogram A Patient&Rsquo;S Own T Cells To Recognize Shared Cancer Targets, Today Announced An Agreement With Novartis To Discover And Develop Novel Tcr-Engineered T Cell Therapies. The Collaboration Includes An Upfront Technology Access Fee And Research Funding Totaling $30 Million, And Potential Milestone Payments Contingent On Clinical, Regulatory And Sales Success That Could Aggregate In The Hundreds Of Millions Of Dollars. The Collaboration Will Leverage Tscan&Rsquo;S Proprietary Platform To Discover Novel Cancer Antigens That May Be Targeted By Tcr-Based Therapies.&Ldquo;As One Of The Only Companies Able To Efficiently Discover Novel Cancer Antigens That Can Be Targeted With Tcr-Based Therapies, We Are Delighted To Be Collaborating With Novartis To Develop Important Tcr Treatments,&Rdquo; Said David P. Southwell, President And Chief Executive Officer, Tscan. &Ldquo;We See Expansive Potential For Our Platform And This Collaboration Gives Us The Opportunity To Work With Novartis To Develop Novel Tcr Therapies, While At The Same Time Preserving Our Ability To Develop Our Own Proprietary Pipeline In Both Liquid And Solid Tumors.&Rdquo;Under The Agreement, Tscan Will Identify And Characterize Tcrs, And Novartis Will Have The Option To License And Develop Tcrs For Up To Three Novel Targets. Novartis Will Also Have Rights Of First Negotiation For Additional Targets And Tcrs That Arise From The Collaboration. In Addition To The Milestones, Novartis Will Pay Tscan Mid-Single To Low Double-Digit Royalties On Net Sales For Each Product. Tscan Is Free To Develop Tcrs Against Targets Not Licensed By Novartis.&Ldquo;Novartis Is A Proven Leader In The Area Of T Cell Therapy, And This Collaboration Helps Us Move Rapidly And Effectively Toward Our Goal Of Delivering Life-Changing Therapies To Patients,&Rdquo; Added Gavin Macbeath, Chief Scientific Officer, Tscan.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!